Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: VPS29

Summary for VPS29

Gene information	Gene symbol	VPS29
	Ensembl ID	ENSG00000111237
	Entrez ID	51699
	Gene name	VPS29 retromer complex component
	Synonyms	DC15\|DC7\|PEP11
	Gene type	protein_coding
	UniProtAcc	Q9UBQ0

Top

Dataset with differentially expressed gene: VPS29

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-0.426318	2.18e-02
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.457562	2.28e-41
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.393395	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.364025	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.512614	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.48063	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.257331	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.349625	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.537745	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.479044	1.65e-26
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.883497	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.536365	7.93e-34
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.272599	3.90e-08
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.549713	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.73961	0.00e+00

Top

Expression of VPS29 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to VPS29

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating VPS29

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
VPS29	hsa-miR-1468-3p	96.4315	NM_001282151
VPS29	hsa-miR-300	94.6107	NM_001282151
VPS29	hsa-miR-381-3p	94.6107	NM_001282151
VPS29	hsa-miR-548t-5p	93.0326	NM_057180
VPS29	hsa-miR-548az-5p	93.0326	NM_057180
VPS29	hsa-miR-3973	92.4185	NM_057180
VPS29	hsa-miR-3646	91.7841	NM_057180
VPS29	hsa-miR-4700-3p	91.3829	NM_057180
VPS29	hsa-miR-656-3p	90.9449	NM_057180
VPS29	hsa-miR-4474-3p	90.1287	NM_001282151
VPS29	hsa-miR-4516	88.9856	NM_057180
VPS29	hsa-miR-6730-5p	88.9264	NM_057180
VPS29	hsa-miR-4307	88.1448	NM_057180
VPS29	hsa-miR-153-5p	87.7544	NM_057180
VPS29	hsa-miR-5000-3p	86.6757	NM_057180
VPS29	hsa-miR-4436a	86.6757	NM_057180
VPS29	hsa-miR-3138	86.1142	NM_057180
VPS29	hsa-miR-329-5p	85.5188	NM_001282151
VPS29	hsa-miR-4666a-3p	85.3729	NM_001282151
VPS29	hsa-miR-5703	85.0351	NM_057180
VPS29	hsa-miR-4434	85.0351	NM_057180
VPS29	hsa-miR-12132	82.2362	NM_057180
VPS29	hsa-miR-335-3p	80.1035	NM_057180

Page: 1

Top

Motifs and transcription factors (TFs) regulating VPS29

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
VPS29	taipale_tf_pairs__MYBL1_ELF1_NMCCGGAACCGTTR_CAP_repr	ELF1; MYBL1 (directAnnotation).
VPS29	jaspar__MA1493.1	HES6 (directAnnotation).
VPS29	metacluster_197.2	E2F4; E2F7; E2F7; E2F7; E2F8; E2F8 (directAnnotation).
VPS29	taipale_tf_pairs__TEAD4_ETV1_RSCGGAAATRCM_CAP	ETV1; TEAD4 (directAnnotation).
VPS29	swissregulon__mm__E2f7	E2F7 (inferredBy_Orthology).
VPS29	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
VPS29	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
VPS29	metacluster_55.5	ZNF541 (directAnnotation).
VPS29	transfac_pro__M05697	ZNF235 (directAnnotation).
VPS29	metacluster_15.4	SMAD6 (directAnnotation). SMAD6 (inferredBy_Orthology).
VPS29	metacluster_27.29	ZNF583 (directAnnotation). ZNF583 (inferredBy_Orthology).

Page: 1

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."